Wells Fargo reiterated coverage on Pulmonx with a new price target
$LUNG
Medical/Dental Instruments
Health Care
Wells Fargo reiterated coverage of Pulmonx with a rating of Equal-Weight and set a new price target of $27.00 from $55.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2024 | $12.00 | Buy | Lake Street |
| 2/23/2024 | $16.00 → $14.00 | Overweight → Equal Weight | Wells Fargo |
| 9/5/2023 | $18.00 | Buy | Craig Hallum |
| 2/27/2023 | $10.00 → $15.00 | Equal Weight → Overweight | Wells Fargo |
| 1/3/2023 | $8.00 | Neutral → Underperform | BofA Securities |
| 12/12/2022 | $14.00 → $10.00 | Neutral → Buy | Citigroup |
| 7/11/2022 | $23.00 → $19.00 | Buy → Neutral | Citigroup |
| 3/2/2022 | $28.00 | Neutral | BofA Securities |
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
SC 13G - Pulmonx Corp (0001127537) (Subject)
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
4 - Pulmonx Corp (0001127537) (Issuer)
4 - Pulmonx Corp (0001127537) (Issuer)
4 - Pulmonx Corp (0001127537) (Issuer)
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights Achieved worldwide revenue of $20.4 million in the third quarter of 2024, a 15% increase over the same period last yearDelivered $13.8 million in U.S. revenue in the third quarter of 2024, representing 17% year-over-year growthRealized gross margin of 74% in the third quarter of 2024Added 15 new Zephyr® Valve U.S. treatment centers in the third quarter of 20246-month data from the AeriSeal® CONV
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chron
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $13.9 million in U.S. revenue in the second quarter of 2024, representing 26% year-over-year growthRealized gross margin of 74% in the second quarter of 2024Added 17 new Zephyr® Valve U.S. treatment centers in the sec
Lake Street initiated coverage of Pulmonx with a rating of Buy and set a new price target of $12.00
Wells Fargo downgraded Pulmonx from Overweight to Equal Weight and set a new price target of $14.00 from $16.00 previously
Craig Hallum initiated coverage of Pulmonx with a rating of Buy and set a new price target of $18.00
10-Q - Pulmonx Corp (0001127537) (Filer)
8-K - Pulmonx Corp (0001127537) (Filer)
10-Q - Pulmonx Corp (0001127537) (Filer)
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights Achieved worldwide revenue of $20.4 million in the third quarter of 2024, a 15% increase over the same period last yearDelivered $13.8 million in U.S. revenue in the third quarter of 2024, representing 17% year-over-year growthRealized gross margin of 74% in the third quarter of 2024Added 15 new Zephyr® Valve U.S. treatment centers in the third quarter of 20246-month data from the AeriSeal® CONV
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chron
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits to patients treated with Zephyr® Valves REDWOOD CITY, Calif. & VIENNA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, announced the presentation of clinical data from the AeriSeal® CONVERT trial and 5-year follow-up data from the LIBERATE study at the European Respiratory Society (ERS) Congress in Vienna, Austria. Presented data from the CONVERT trial demonstrated that treatment wi
Lake Street analyst Frank Takkinen initiates coverage on Pulmonx (NASDAQ:LUNG) with a Buy rating and announces Price Target of $12.
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday. Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results. C.H. Robinson Worldwide posted adjusted earnings of 86 cents per share, beating market estimates of 82 cents per share. The company's quarterly sales came in at $4.412 billion versus expectations of $4.269 billion, according to data from Benzinga Pro. C.H. Robinson Worldwide shares jumped 16.8% to $84.24 on Thursday. Here are some other big stocks recording gains in today's session. Aspen Aerogels, Inc. (NYSE:ASPN) jumpe
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of
LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir